Open access
Aug 2026
Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer.
A small molecule inhibitor is repurposed to interfere with its binding to DNA, restrict chromatin accessibility at promoters, and constrain tumor growth both in vitro and in vivo to show how increased HMGB2 availability represents a transcriptional addiction that fuels cell-cycle progression and growth.
Adi Danieli-Mackay, Ioanna Papadionysiou, Markos Tsitsianopoulos et al.
· Cell Reports · 0 citations